You are here

FDA Accepts IND for Optina (Danazol) for Treatment of Diabetic Macular Edema

Clinical trial expected in first quarter, 2013 (Jan. 22)

The planned multicenter trial will evaluate the safety and efficacy of 12 weeks of treatment with oral Optina compared with placebo in adult patients with DME. The patients will be randomized to receive one of two dosages of Optina (0.5 mg per BMI or 1.0 mg per BMI per day) or placebo. After the patients have completed 4 weeks of initial treatment, an interim analysis will determine the best dose of Optina. Following the 12-week active treatment period, there will be a further 4-week washout period. The primary endpoint is improvement in visual acuity, defined by responder status, compared with placebo. Following treatment and washout, the patients will be assessed for vision regression, and a 12-week open-label extension study will be offered to evaluate the duration of the effect of the optimal dose. A total of 450 patients are expected to enroll.

Optina is a drug based on a low dose of danazol mdash; a weak androgen, low-molecular-weight, lipophilic steroid. In vitro data suggest that danazol has a biphasic effect on endothelial cells: at low doses, the drug decreases vascular leakage, while at higher concentrations an increase in vascular permeability is observed.

Source: Ampio Pharmaceticals; January 22, 2013.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs